The Impact of Liquid Biopsies on Clinical Practice in Oncology

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Clinical Medicine, Cell, and Organism Physiology".

Deadline for manuscript submissions: 31 December 2024 | Viewed by 161

Special Issue Editors

E-Mail Website
Guest Editor
Department of Cell Biology and Physiology, Brigham Young University, Provo, UT, USA
Interests: liquid biopsy; exosomes; cancer; gastrointestinal cancer; extracellular vesicles

E-Mail Website
Guest Editor
Division of Surgical Oncology, University of California Irvine, 3800 Chapman Ave, Ste 6400, Orange, CA 92868, USA
Interests: oncology; peritoneal carcinomatosis; exosomes; gastrointestinal cancer; extracellular vesicles; cancer

Special Issue Information

Dear Colleagues,

Current modalities of imaging and tissue biopsies, while essential to current tumor monitoring and characterization, have significant weaknesses that “liquid biopsies” seek to address. Liquid biopsies promise a novel approach to detecting tumor presence, growth, and recurrence. The term was first introduced with a focus on circulating tumor cells (CTCs) but has since broadened to include cell-free DNA (cfDNA)/circulating tumor DNA (ctDNA), extracellular vesicles, exosomes, tumor-educated platelets (TEPs), and various forms of circulating RNA. While the development of liquid biopsy tools is a very active focus of research, the translation of the work for use in oncology remains an urgent need for improved patient care and the implementation of personalized treatment decision-making. The aim of this Special Issue is to highlight the work that is being carried out to develop liquid biopsies into practical clinical applications. Among other topics, we are seeking original research and review articles that elucidate the successes and weaknesses of the clinical implementation of liquid biopsies, identify biomarkers and analytes of clinically actionable cancer progression, illustrate strategies for the translation of potential liquid biopsy targets into the oncology clinic, or explore the application of liquid biopsy tools for prognostic or therapeutic guidance.

Dr. Amber Gonda
Dr. Maheswari Senthil
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • liquid biopsy
  • ctDNA
  • CTC
  • extracellular vesicles
  • exosome
  • oncology
  • cancer

Published Papers

This special issue is now open for submission.
Back to TopTop